Targeted Nanoparticles To Deliver Combinations Of Calcium Channel Inhibitors To Prevent Myelin Damage During Secondary Degeneration After Neurotrauma
Funder
National Health and Medical Research Council
Funding Amount
$895,244.00
Summary
Following injury to the central nervous system the damage spreads into nearby areas, leading to worse outcomes for the patient. We will generate nanoparticle systems to deliver effective therapies directly to the most vulnerable cells, critical for function. We will modify the nanoparticles so that they can get to the injury site, both early after injury, and after longer periods of time have elapsed. We will then test the nanoparticle systems to see if they are effective at preserving function
Regulating Astrocytosis For Appropriate Defence And Repair Of The Brain After Injury
Funder
National Health and Medical Research Council
Funding Amount
$562,742.00
Summary
An inflammatory process, designed to clean up cell debris and maintain tissue integrity following brain insult, also results in an astrocytic scar that biochemically impedes nerve repair. After 8 weeks astrocytes switch to become supportive, however once a scar is formed repair is permanently inhibited. Here, we will test the ability of biomaterials to optimise the timing of the necessary inflammatory phase, to encourage repair by converting astrocytes to their tropic phase more rapidly.
Improving Therapeutic Delivery By Understanding Nanoparticle Interactions With Cells
Funder
National Health and Medical Research Council
Funding Amount
$553,152.00
Summary
Nanotechnology has the potential to transform the way we treat many diseases. This project will investigate how nanoengineered particles can be used to improve the effectiveness of vaccines. Nanoparticles can protect the delicate vaccine cargo from degradation, and will be targeted specifically to the cells in the body that most effectively induce the maximum theraputic response. This study will improve our understanding of how nanovaccines work and develop new ways of delivering vaccines.
Investigation Into The Intervention Of Arterial Thrombosis And Atherosclerosis Using Shear Sensitive Nanoparticle Drug Delivery
Funder
National Health and Medical Research Council
Funding Amount
$462,601.00
Summary
In this project we aim to provide a targeted therapy that inhibits atherosclerosis, in-stent restenosis and thrombosis; pathologies characterized by high shear stress due to a reduction in the vessel lumen. We will apply microfluidic technology to characterize lipid nano-capsules that are tagged with antibodies against activated platelets or VCAM-1, loaded with anti-platelet or immune suppressive drugs and are prone to rupture specifically under high shear stress conditions.
Immunological And Respiratory Effects Among Workers Exposed To Engineered Nanoparticles
Funder
National Health and Medical Research Council
Funding Amount
$513,507.00
Summary
Laboratory studies suggest that nanoparticles can easily enter the body and may cause more damage than similar, larger particles but human data are lacking. We propose to study the health of nanoparticle-exposed workers and unexposed workers, and compare biomarkers of inflammation in the blood and the respiratory system at the start and end of the shift, end of the working week and after 1 year’s further exposure to nanoparticles.
Novel Targeted PEG Nanoparticles For Cancer Treatment And Monitoring
Funder
National Health and Medical Research Council
Funding Amount
$606,979.00
Summary
We will develop novel targeted cancer therapies based on next generation nanoparticles. These particles will deliver highly potent drugs to tumours with less adverse effects to healthy organs. The ability to image the therapeutic can be used to detect diseases at early, potentially curable stages, identify patients likely to respond to certain treatments, and predict response to therapy. Our project has the potential to increase the survival of patients suffering from the most deadly cancer.
Improving Cancer Diagnostic Imaging And Drug Delivery By Breaking Down Extracellular Matrix Barriers
Funder
National Health and Medical Research Council
Funding Amount
$748,152.00
Summary
Solid tumours are stiffer than normal tissues. This stiffness is caused by over-production of non-cellular components known as extracellular matrix (ECM). ECM creates a barrier that restricts drug access in tumours. New methods to overcome tumour stiffness are crucial to improve drug delivery. We will study the use of a new compound to degrade tumour ECM to improve anti-cancer drug delivery. Our compound will be useful in treatment-resistant solid tumours such as breast and liver cancers.
Biomaterials For The Direct Reprograming Of Reactive Astrocytes Into Functional Neurons
Funder
National Health and Medical Research Council
Funding Amount
$630,500.00
Summary
We will employ peptide inspired hydrogel nanoscaffolds that can be injected into a brain lesion as a single injection to provide chemical and physical support for the surrounding cells. We will utilize various modifications to these materials to reprogram inflammatory cells into neurons, whilst also promoting the survival, maintenance and growth of existing neurons to encourage repair.
Understanding The Cellular Processing Of Targeted Nanoparticles For Improved Therapeutic Outcomes
Funder
National Health and Medical Research Council
Funding Amount
$625,477.00
Summary
Nanotechnology has the potential to transform the way we treat many diseases. This project will investigate how nanoengineered particles can be used to improve the effectiveness of vaccines. Nanoparticles can protect the delicate vaccine cargo from degradation, and will be targeted specifically to the cells in the body that most effectively induce the maximum theraputic response. This study will improve our understanding of how nanovaccines work and develop new ways of delivering vaccines.
Nanomedicine Targeted Delivery Of Therapeutics To The Placenta To Treat Preeclampsia
Funder
National Health and Medical Research Council
Funding Amount
$513,148.00
Summary
Preeclampsia, one of the most serious complications of pregnancy, affects around 3-8% of all pregnancies. Sadly, there is no treatment. We have developed a new technique to deliver treatments only to the placenta, sparing the mother and baby from side effects. We will test whether this technique can treat the source of preeclampsia, the placenta, in human and mouse models in our laboratory. This work has potential to offer possibilities of new treatments to other pregnancy complications.